CSIR has geared itself to face the challenges in the Healthcare, Drugs and Pharmaceuticals sector by taking several measures such as prioritization of research programmes, creation of state-of the- art facilities, induction of new talent and most importantly, establishing linkages within CSIR and with other national agencies/industry.
The projects networking CSIR laboratories, other R&D institutions, and industry to capitalize on their combined strength include those on: new drugs based on our traditional knowledge, biodiversity, marine resources, search for new molecular targets for selected pathogens, in-silico biology, predictive medicine, new animal models and animal substitute technologies, etc.
Recent advances in biology such as genome sequencing have opened up unlimited opportunities in medicine. After deciphering sequence of genes (structural genomics), it is now possible to elucidate their function (functional genomics). Ultimately it is believed that through proteomics, new disease markers and drug targets can be identified that will help design products to prevent, diagnose and treat disease. Technologies of combinatorial synthesis and high-throughput screening (HTS) offer the potential to speed up the pace of drug research and reduce the time and cost of investment in drug discovery. All these tools and techniques and research disciplines are now being applied in current R&D programmes of many CSIR laboratories in order to become internationally competitive.
That CSIR has made valuable contributions to the industry and the society in this vital sector are amply reflected by the development of several novel drugs, which have been successfully commercialized by the industry, and are currently marketed (Saheli, E-mal, Elubaquin, Promind, Asmon, etc.), and dozens of process technologies leading to commercial production of high-value drugs/drug intermediates (l-ephedrine, dextropropoxyphene hydrochloride, artemether, cetrizine, amlodipine, naltrexone, ciprofloxacin, streptokinase, etc.) and their import substitution. A recent discovery is that of a novel anti-TB molecule, which has been found after sixty years since the last molecule discovered for this dreaded disease. The molecule, Sudoterb reduces the treatment time to 2 months from 6-8 months and has lesser side effects.
CSIR's composite mandate in the sector covers a large spectrum of activities, and it may be summed up as: Broad-based, multi-disciplinary research — basic, exploratory and applied — in order to develop suitable knowledge-based products, processes and interventions; to investigate and advise on abatement and control of environmental and industrial health hazards; and to provide testing and analytical services, contract research, consultancy, information services and training for development of human resource. The products developed, viz., new drugs, diagnostics, vaccines, herbal medicines, nutraceuticals, inventions, devices and gadgets for monitoring air, water, food contaminants/adulterants, will comply with international regulatory requirements, quality and standards."
|Labs||Areas of Core Competence|
|Central Drug Research Institute (CDRI, Lucknow)||Drug discovery to development, synthetic/natural product chemistry, combinatorial chemical synthesis, molecular modelling, HTS, structural biology, broad-based biological screening, pharmacology, pharmaco-kinetics, toxicology, phase I clinical studies, chemical and fermentation technology, quality control and standardization, proteomics, medicinal chemistry, molecular and cell biology, pharmacology, and phytochemicals/herbal drugs/nutraceuticals research.|
|Indian Institute of Chemical Biology (IICB, Kolkata)||Synthetic/natural products/medicinal chemistry, infectious diseases, cellular physiology, drug designing, molecular modelling, molecular biology, biotechnology, cell signals for oncogene expression and metabolic diseases, immunology, human genetics, genomics, proteomics, bioinformatics, molecular and cell biology, pharmacology, phytochemicals/nutraceuticals.|
|Indian Institute of Chemical Technology (IICT, Hyderabad)||Synthetic and natural products chemistry, chemical /process engineering, combinatorial/medical chemistry, asymmetric synthesis for chiral drugs, custom synthesis, computer-aided modelling and drug design, glyco-therapeutics, peptides and peptido-mimetics, enzyme mimics (drug delivery systems), pharmacology, pre-clinical toxicity pharmacokinetics, toxicology, phytochemicals/herbal drugs/nutraceuticals research, quality control and formulation.|
|Indian Institute of Microbial Technology (IMTECH, Chandigarh)||Molecular and cell biology, microbial genetics, immunology, structural biology, protein engineering, fermentation technology, culture type depository, microbial gene bank, bioinformatics, proteomics, molecular and cell biology.|
|Institute of Genomics and Integrative Biology (IGIB, Delhi)||Genomics & Molecular Medicine, Predictive medicine, Genome Informatics (in-silico biology), Bio-informatics, Pathway modelling, Proteomics structural biology, Comparative Genomics & Gene Expression, Immunology and molecular genetics of respiratory disorders including allergy, Nucleic Acids & Peptides, Bioactive molecules of medicinal importance.|
|Regional Research Laboratory (RRL-Jammu)||Agrotechnology, synthetic (chiral) and natural product chemistry, herbal drugs, select biological screening, bioprospecting, microbial biodiversity for industrially useful enzymes, genetic fingerprinting, identification/authentication of medicinal plants, fermentation technology, quality control and standardization of herbal drugs, establishment of medicinal plants gene bank, bioinformatics, pharmacology phytochemicals/herbal drugs/nutraceuticals research.|
|Central Institute of Medicinal and Aromatic Plants (CIMAP, Lucknow)||Agrotechnology of economically important herbs, process technology for phytochemicals, herbal drugs, nutraceuticals, genetic finger printing of plants/herbs, plant bioinformatics, genetic improvement, bioprospecting, molecular and cell biology, quality control and formulation.|
|Centre for Cellular and Molecular Biology (CCMB, Hyderabad)||Advanced molecular and cell biology, biotechnology, sperm-associated proteins/fertility-potential of sperm, DNA-fingerprinting, signal transduction, eye diseases, hepatitis vaccine, microbial genetics, transgenics, anti-microbial proteins, genomics, proteomics molecular and cell biology|
|National Chemical Laboratory (NCL, Pune)||Synthetic chemistry, tissue culture, biotechnology, industrial microbiology, nanoparticle technology, smart polymer gels, chemical/process engineering, process/enzyme/fermentation technology, combinatorial chemistry, medicinal chemistry, quality control and formulation|
|Institute of Himalayan Bioresource Technology (IHBT, Palampur)||Identification, collection, isolation and characterization of plants and microbes chemical and molecular characterization of bioactives, genomics, tissue culture, agro-technology of medicinal plants, phytochemicals/herbal drugs/nutraceuticals research, and chemical/process engineering|
|Industrial Toxicology Research Centre (ITRC, Lucknow)||In vitro test systems for bio-evaluation/identification of molecules or neurological disorders and antioxidant activity, complete toxicity evaluation in small animals; identification and action mode of hazardous toxicants/pollutants, diagnostics for toxicants/pollutants; safety evaluation/preventive measures for environmental/industrial hazards, and quality assessment of drinking water|
|National Botanical Research Institute (NBRI, Lucknow)||Pharmacognosy, ethnopharmacology, herbal drugs (authentication, standardization, characterization), nutraceuticals, agro-technology of medicinal plants, plant bioinformatics, genetic characterization and genetic improvement of economically important plants, proteomics, transgenics, molecular and cell biology, pharmacology, phytochemicals/herbal drugs, quality control and formulation|
|Central Salt & Marine Chemicals Research Institute (CSMCRI, Bhavnagar),||Bioactives from plants, cultivation of desert economic plants and their value addition, sea weed cultivation, phycocolloids and marine microbes, biotechnology, synthetic chemistry and drug intermediates desalination water treatment technology for pure water for drinking, low sodium and plant/herbal salt|
|Regional Research Laboratory (RRL, Jorhat).||Bioactives from plants, drugs and drug intermediates, isolation and characterization of active molecules and analytical services|
|National Institute of Oceanography (NIO, Goa)||Collection and identification of marine flora and fauna, biological screening (antimicrobial, anticancer, oxytocic, anti-inflammatory, anti-fouling cytotoxic, antimalarial, antiosteoporotic antiviral, immunomodulatory) and marine natural product chemistry for the identification and structure elucidation of active molecules|
|Regional Research Laboratory (RRL-Thiruvananthapuram)||Synthesis of drugs/drug intermediates, natural product isolation, biological screening, chemical finger printing, herbal drugs, nutraceuticals, bioprocess/enzyme technology and phytochemicals.|
|Central Food Technological Research Institute (CFTRI, Mysore)||Nutraceuticals, health-promoting effects of spices/herbs/foods (antioxidants, digestion-stimulants, anti-inflammatory), traditional remedies, food-safety/nutritional toxicology, nodal codex food laboratory, animal and plant cell culture, PCR probes and biosensors, phytochemicals/nutraceuticals research, quality control & formulation, toxicology and bioprocess/enzyme/fermentation technology|
|Central Leather Research Institute (CLRI, Chennai)||Controlled drug delivery systems, collagen-based biomaterials, skin biology|
|Central Glass and Ceramics Research Institute (CGCRI, Kolkata||Ceramic membrane technology based water purification technologies, Ceramic based bio-medical implants|
|National Environmental Engineering Research Institute (NEERI, Nagpur)||Water purification, diagnostic kits etc.|
Knowledge-based Products/Technologies Developed and Basic Findings
CSIR has earned the distinction of developing 11 out of the 16 new drugs developed in India. It has developed cost effective and innovative processes for around 25 generic drugs, standardization of over 50 herbal drugs and devised new diagnostic tools. The production of over 25 drugs/drug intermediates, technologies for which have been developed and successfully commercialized, is valued at around Rs 600 million annually. Several of these drugs are exported and save net foreign exchange through export substitution. Some of the major accomplishments are as follows:
- Centchroman, a safe and effective non-steroidal, oral contraceptive for women, has been commercialized by Hindustan Latex Ltd, Thiruvananthapuram, under the trade name Saheli.
- Arteether, a blood schizontocidal anti-malarial developed as result of joint effort of CIMAP and CDRI, marketed by Themis Ltd., Mumbai as E-Mal.
- Elubaquine, an anti-relapse, anti-malarial effective against Plasmodium vivax, commercialized by Nicholas Piramal, Mumbai, under the brand name Aablaquin.
- Standardized extract of Bacopa monnieri developed for memory improvement, manufactured and marketed by Lumen Marketing Company, Chennai, under the trade name Promind.
- Asmon, a polyherbal standardized drug for asthma, commercialized by Herbochem Remedies India Limited, Kolkata.
- Consap cream, spermicidal, contains saponins derived from Sapindus mulkrossi or soapnut, soon to be marketed by Hindustan Latex Ltd.
- Kollagan and Neuskin, biological dressings for burns, open wounds and ulcers, developed by using bovine tissues, commercialized by Eucare Pharmaceuticals Pvt Ltd, Chennai.
- Sallaki, an anti-inflammatory drug for the treatment of rheumatoid arthritis and osteoarthritis produced from Boswellia serrata, marketed by M/S Gufic (P) Ltd., Mumbai.
- Livzon, a multiherbal formulation with hepatoprotective properties, marketed by M/s Hind Chemicals Ltd., Kanpur.
- Imminex, a multiherbal formulation with immunomodulatory properties, marketed by M/s Hind Chemicals Ltd., Kanpur.
- Safe, eco-friendly, health protective cosmetic composition containing natural colours developed from medicinal herbs, fortified with various aromas. Technology transferred to M/s Ayur Herbal (Pvt.) Ltd.
Products Available for Licensing/Commercialization
- Tinospora cardifolia has been identified as a huge source of saccharifying -amylase in purest form, present in the aqueous extract of the stem. The enzyme has tremendous potential to be used as the safest -amylase of plant origin in pharmaceutical preparations. This has been patented by IICB.
- Nutraceuticals; over 21 preparations have been developed and their trademark registered. These are nutritional supplements for pregnant women and lactating mothers, cardiotonic, hepatoprotective, general tonics etc.
- Genetically engineered oral cholera vaccine, has been developed in a collaborative project of IMTECH, NICED and IICB and based on recombinant strain of V. cholerae ‘VAL3’ is currently under phase II clinical trials.
- Can NIO 450 anxiolytic.
- Enzymatic processes for Naproxen resolution, Paroxetine intermediate resolution, Flauxetine intermediate resolution, Gluconate salts
- NMITLI-HA-002, a multi herbal formulation as hepatoprotective against alcoholic cirrhosis and viral cirrhosis under multicentric clinical trials
- VIJAYSAR, a single plant based anti-diabetic drug under multicentric clinical trials sponsored by ICMR.
- End to end technology on Hypericum perforatum a mild anti-depressant, passed on to M/S Nicholas Piramal Ltd., Mumbai.
- Anticancer- lead molecules/extracts
- Hepatoprotective– single molecule
- An antigen-based ELISA diagnostic kit has been developed for allergic bronchopulmonary Aspergillosis. It is a sensitive and specific test for early diagnosis of the infection.
- A diagnostic kit for alpha-fetoprotein for detection of foetal abnormalities has been commercialized by Shantha Biotech
- Low-cost analytical tests for detection of adulterants in oils and fats.
- Tests for detection of food-borne pathogens using gene probes through PCR technique.
- Multiplex PCR based methods for the detection of food-borne pathogens that are adversely affecting the quality of food products such as milk, walnut kernels, soft drinks, water and apple juice concentrate. This technology would lead to the development of diagnostic kits.
- Development of plant-based adjuvants: RRL Jammu is involved in the development of plant based molecules for use with anti-hepatitis vaccine as adjuvant replacing Al(OH)3. DST and Bharat Biotech Ltd have extended financial support. One of the molecules, RLJ-NE-299A is in the advanced stage of its development as an adjuvant.
Enzyme Mimics from CSIR
- Cyclodextrin-based chemosensors have been developed as ‘artificial receptors’ for molecular recognition of organic compounds, which may find use in the detection of drugs.
- Dynamic kinetic resolution has been achieved using cyclodextrins under supramolecular catalysis for the first time to get single enantiomer from the racemic substrates. The strategy is being used to develop single enantiomer drugs.
- Cyclodextrin based drug delivery systems have been developed for rifampicin to improve its bioavailability in fixed dose combinations.
Products Developed/Under Development
- A potential therapeutic agent from herbal source for chronic myelogenous leukaemia, which is 80% of total blood cancers has been developed by IICB. This is a unique plant-based compound, which specifically targets the cancer cell and does not have any effect on neighbouring cells. In case of cancer, this particular property is the most important as chemotherapy has tremendous side effect.
- RRL Jammu has identified more than 20 extracts/fractions showing various promising activities. Out of these, AP9cd and RJM 0125 P04 A003 are strong candidates for development as specific anticancer drugs. In addition certain leads obtained in this institute are being further investigated by sister laboratories as anti-hypertensive agent (RJM 0035 P10 A001), for the treatment of Filaria (RJM 0069 P03 A003) and Parkinson’s disease (RJM 0168 P03 A001, RJM 0410 P13 A003).
- Some important leads are trioxane molecules (anti-malarials), plant products (anti-filarial), IICT-18719 (anti-HIV), jorumycin isolated from a nudibranch (anti-tumour), broad-spectrum antibiotic from Streptomyces sp201, HIV-1 protease inhibitor.
- Nutraceuticals development covers products for prevention of coronary heart disease, antioxidants (carotenoids, tocopherols, polyphenols, oryzanols), digestion stimulators, anti-inflammatory, anti-diabetics, bioavailability/bioefficiency enhancers.
- Herbal therapeutics: This includes 97 M - an Iridoid glycoside mixture isolated from Vitex sp as hepato-protective against alcoholic cirrhosis and viral cirrhosis and Acteocide–a single molecule drug for hepatoprotection. Out of the eleven plant-based molecules which have been identified as immunomostimulators, RLJ-NE-299A is at an advanced stage of its development as an adjuvant with hepatitis vaccine replacing AL(OH)3.
- Biomaterials have been prepared from reconstituted human amnion for in vitro culture of fibroblasts, with potential application as dressings in open wounds. Chemically modified bovine collagen, which forms a clear solution, has been used to prepare collagen shields and bandage lenses, for use in cataract surgery. A collagen membrane has also been prepared for use in periodontal surgery.
- The following generic drug technologies have been commercialized:
- l-Ephedrine hydrochloride (broncho-dilator), dextroproxyphene hydrochloride (analgesic) Arteether (anti-malarial), Amlodipine (Calcium channel blocker), Naltrexone (anti-alcoholic).
- Streptokinase (thrombolytic): Technology for the production and purification of therapeutic-grade streptokinase, used in myocardial infarction and other disorders, has been commercialized by Cadila Pharmaceuticals Ltd. Ahmedabad, under the trade name STPase.
- Process for extraction of high molecular weight hyaluronic acid, suitable for use in ophthalmic surgery, has been released to Cadila Laboratories
- Technology for the production of calcium gluconate, for use as a calcium supplement by humans and poultry, has been licensed to Pratishta Industries, Hyderabad.
- A cost-effective enzymatic process for rifamycin B to rifamycin S (almost 100 per cent yield) has been developed by using IMTECH isolate. The process obviates the use of harsh chemical treatments involving oxidative and corrosive agents. The technology has been licensed to two companies.
- Technologies for Hip-joint prosthesis and artificial eyeballs transferred to a Kolkata-based industry.
- Technology of arsenic and iron removal from sub-surface water to produce safe drinking water has been recognized by the Government of West Bengal and the Department of Science and Technology, Government of India for setting up several of demonstration plants of different capacities in West Bengal and North Eastern States.
- Multi-functional mini pilot scale fermentor: RRL has designed and fabricated a microprocessor controlled 75 to 100 litre fermentor with in situ autoclaving facilities. The pilot plant has been successfully installed and commissioned at a number of places under consultancy programme. The total cost of the each unit is approximately Rs. 1.5 million. The plant has all the features of an R&D pilot scale fermentor wherein distributed parameters and variables can be studied. It can also be used as a production plant for high-value, low-volume products, even for genetically engineered organisms.
- Know-how for clones for expressing Lysostaphin, r-CGF, r-streptokinase and r-proinsulin licensed to Bharat Biotech International, Hyderabad
- Rights for marketing of a bio-informatics software tool, PL-HOSTFA assigned to Jalaja Tech, Hyderabad.
Technologies Available for Licensing/Commercialisation
- Generic drug technologies: Lacidipine, losartan-K doxazocin, mefloquin, pyrazinamide, pentazocine, nitrazepam, o-aminobenzophenone, vitamin-B6.
- Transgenic flies for drug screening.
- Heterogeneous catalysts for preparation of aryl propanoic acid used as intermediate in the synthesis of ibuprofen and naproxen.
- Know-how for urokinase, used for dissolving blood clot.
- Custom made peptides.
- Process for isolation of cyclosporin A from marine fungus, Fusarium nivale.
- Technology for gene delivery using cationic amphiphiles.
- Processes for the preparation of reconstituted collagen substratum, reconstituted collagen sponge, transparent soft collagen film, novel fibrin sponge, and novel cross-linked collagen sheet have been developed for medical applications.
- Technologies for the preparation of hepatoprotective agents, immunomodulators, anti-diabetic and anti-arthritic agents.
- Technology for phytopharmaceuticals viz. Colchicine, Colchicoside, Silymarin, Boswellic acids, Diosgenin, 16-DPA, Berberis hydrochloride and Rutin.
- Seapath: A bio-informatics software tool for identifying adhesin and adhesin-like proteins useful for developing new therapeutics.
- Gene-decipher. A bio-informatics software tool for identifying protein coding DNA sequences useful as potential drug targets.
- A rapid method of enzyme linked immuno-sorbent assay (ELISA).
- Monitoring of BOD and COD.
- Rapid method for estimation of chemical oxygen demand (COD)
- A reusable immobilized microbial formulation for use in BOD analysis.
- BOD Sensor: Immobilized microbial consortium useful for rapid and reliable BOD estimation.
- Know how for biological neutralization of alkaline industrial effluents.
Technologies Developed/Under development
- IICT has taken up the improvement in the process for Ranitidine, Omeprazole, and Ciprofloxacin to realize maximum conversion, replacement of hazardous intermediates and solvents.
- Studies to understand the structure function aspects of staphylokinase (SAK) and develop its new variants carrying functional units of both SAK and streptokinase (SK) in order to generate new molecule with improved properties.
- Preparation of cell beads BOD sensor, useful for instant BOD estimation
- A biological process for colour reduction of pulp and paper effluent
- Preparation of an immobilized microbial consortium for the treatment of phenolic wastewater.
- An aerobic biological method of removing total dissolved solids from tannery wastewater.
- A novel method for preparing novel anti-hypertensive molecules.
- Detection of pathogenic Mycobacteria in clinical specimens
- DNA based diagnostic methods for prediction of predisposition to certain diseases:
- Method of detection of allelic variants of Spino cerebellar ataxia 2 gene.
- Novel primers for screening schizophrenia and a method thereof.
- A method for the detection of predisposition to High Altitude Pulmonary Edema
- A method of detecting predisposition to atopic disoders by screening for human (Stat 6) gene variants
- A method of detection of SP-A2 gene variants useful for prediction of predisposition to pulmonary tuberculosis
- Genetic variants of human Transforming Growth Factor BetaI (TGFBI) and prediction of immunological disorders.
- Detection of MBL gene variants useful for prediction of predisposition to bronchial asthma with allergic rhinitis.
- Pharmacogenomics (Variable Drug response)
- A method for predicting an individual’s bronchodilatory response to a beta agonist.
- Novel allelic variant of CYP2C19 associated with drug metabolism.
- Immobilization/bioassay of biomolecules:
- A simple, efficient and accelerated method for enzyme catalyzed in vitro modification and synthesis of Nucleic acid using microwave irradiation.
- A significant breakthrough in chemical degradation of diosgenin, a major raw material used in the synthesis of corticosteroids, sex hormones and anti-fertility compounds.
- CDRI and Bharat Biotech International Ltd., Hyderabad, are collaborating under NIMTECHU project for the development of Lysostaphin as a drug for treatment of staphylococcal infection.
- A biocatalytic kinetic resolution method has been developed for the preparation of enantiomerically pure (S)-(+) –flurbiprofen in more than 99% purity. At present, sales of these drugs are permitted as racemates. A collagen membrane has also been prepared for use in periodontal surgery.
- CGCRI has developed a new process for the recovery of low sodium salt (mixture of NaCl and KCl).
- Developing anti-diabetic marketable products of plant origin.
- End to end technology of Tinospora cordifolia for the production of standardized extract.
- Up-scaling and standardizing the process for the production of enriched extract of 1,25-dihydroxy Vitamin D3 from a plant source as an anti-psoriasis agent.
- Combinatorial facilities have led to synthesis of libraries with several ‘hits’ and ‘lead compounds’ from 3-isoxazoles, glycoconjugates of galacto-pyransylated amino alcohols and thiazine-thiones.
- The formulation of a novel hemiacetal during ‘Baylis-Hillman’ reaction of substituted aldehydes (substitutes of 5-isoxazole carboxaldehyde and substituted benzaldehydes) with cyclohexenone has been established for the first time.
- Discovery of the underlying mechanism of drug resistance in Mycobacteria reveals a multi-drug-resistance pump in M. smegmatis, which is often used as a model system for M. tuberculosis, holds promise in developing a detection system for drug-resistant Mycobacteria.
- Bioactive lead molecules have been identified with potential for developing antifungal and anti-asthmatic drugs.
- Identification of Protein tyrosine phosphatases and Protein kinase F of M. tuberculosis as potential drug targets.
- Studies of smart polymer gels, have demonstrated for the first time that a fine balance between hydrogen bonding and hydrophobic interactions is responsible for transformation from swollen to the collapsed state. The ‘intelligent’ response of such gels can be utilized in novel applications such as controlled drug delivery.
- A drug target inositol-1 phosphate synthase enzyme has been identified in tuberculosis bacillus. This enzyme has already been cloned and expressed at IMTECH and efforts are on to overexpress it so that an assay for high throughput screening of chemical libraries can be set up.
- Studies at IMTECH on structural elements in streptokinase (SK), which confer high affinity to this protein for plasminogen, has led to a comprehensive model to explain the mechanism of action of SK.
- Human lung surfactant proteins SP-A and SP-D have been identified as therapeutic agents for Aspergillosis and other respiratory allergic and infectious diseases for the first time.
- Studies on selected genotypes of opium poppy have led to development of genotypes with high thebine, codeine and narcotine contents.
Recent advances in molecular biology, sequencing of human genome, computational biology, protein sciences, development of nanotechnology and electronics have given rise to a wave of new disciplines aided and supported by new laboratory techniques and tools. The recent advances in genomics and proteomics are providing new insights into the better understanding of living functions and their possible use in abatement of diseases and health risks. While automation of various techniques and use of computers has increased efficiency, accuracy and speed, the magnitude of data generated poses problems of storage, analysis and interpretation.
With initial success of bio-ceramic research, efforts are directed to develop different types of innovative implants and devices, drug delivery systems, sensors, tendons, ligaments, artificial organs etc. As a part of programme of technology demonstration a few projects funded by DST, New Delhi and National Drinking Water Mission are planned to be pursued viz. a) setting up iron-removal plants in N-E States and West Bengal; b) fabrication of high-capacity ceramic membrane module and arsenic removal plants for attachment to contaminated deep tube wells; c) standardization and up-scaling of manufacturing process of multi-channel ceramic elements required for designing high capacity arsenic removal plants.
While the picture on the discovery front looks grim, new approaches emerging in therapeutic arena pose yet another challenge to chemotherapy. Though genomics opens new opportunities to develop safer drugs, the use of drugs developed in post-genomic era will be restricted in use. The application of pharmacogenetics will lead to designing of drugs based on the genetic make-up of a given population with the result that such drugs will have use only in a sub-set of patient population, that is, a restricted market compared to the current blockbuster drugs which capture huge markets. The targeted drugs will be, however, more effective, safer and would take lesser time for development. The recent developments in biology, which are expected to cause far-reaching impact on conventional therapy in future, are ‘gene therapy’ and ‘stem cell research’.
It is envisaged that in the near future, the biotechnology market, a sizeable percentage of which comprises biopharmaceuticals, will open up yet wider. India has an immense opportunity in the pharma sector in the areas of product development and licensing, contract research, knowledge-based services and routine quality S&T services in order to serve the country’s long term S&T and economic interests.